Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04899050 · ClinicalTrials.gov registry record · Phase 4
Epidiolex in Typical Absence Seizures
A Phase 4 study, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT04899050: Completed Phase 4 study, sponsored by University of South Florida.
NCT04899050 is a Phase 4 study that has completed, run by University of South Florida. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04899050, a Phase 4 study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Pilot study, open-label study consisting of a screening period of up to 4 weeks, a 4-week dose-titration treatment period to dose of up to 20 mg/kg/day BID of CBD (Epidiolex), and a 30 day safety follow-up period following the last dose of study medication.
Primary Outcome
The EEG epileptiform activity will be measured in seconds per 24 hours period.
Interventions
- DRUG Cannabidiol (Epidiolex)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-07-30 |
| Est. Completion | 2023-05-27 |
| Phase | Phase 4 |
What the finished NCT04899050 record still lists
NCT04899050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Cannabidiol (Epidiolex) is the first listed.
NCT04899050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04899050 about?
NCT04899050 is a clinical study titled "Epidiolex in Typical Absence Seizures". This is a Pilot study, open-label study consisting of a screening period of up to 4 weeks, a 4-week dose-titration treatment period to dose of up to 20 mg/kg/day BID of CBD (Epidiolex), and a 30 day safety follow-up period following the last dose of study medication.
What is the current status of trial NCT04899050?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2021-07-30. Estimated completion is 2023-05-27.
What interventions are being tested in trial NCT04899050?
The interventions under investigation include: Cannabidiol (Epidiolex) (DRUG).
Who is sponsoring clinical trial NCT04899050?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04899050's enrollment target sits among peer trials
14 1901st of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy